Oncolytics Biotech Inc ONCY

San Antonio Breast Cancer Symposum (SABCS) December 2022

[pelaboost]

I was reading a release dated December 8, 2022 that pertains to the bridging study. Worth reading.

Of Note.

Thirteen of 14 (93%) evaluable patients achieved disease control, with 12 (86%) showing tumor shrinkage.

One patient achieving a PR at week 8 has maintained the PR through week 48 and remains on study.

The data cut-off date was September 26, 2022.

Adlai Nortye has done some top shelf work.

[Noteable]

These patients would be added to the Phase 2 BRACELET-1 pelareorep + paclitaxel cohort numbers and become what ONCY needs for the start of a Phase 3 clinicak trial and potential FDA Accelerated Approval request in 2L metastatic breast cancer.

[Noteable]

Previously posted:   Aware-1 identified pelareorep biomarkers in HR+/HER2- early-stage breast cancer that satisfy the FDAs use of surrogate endpoints/biomarkers in its Accelerated Approval pathway and pelareoreps early approval filing in mBC. - Pelareorep alone and with checkpoint blockade converts tumors to PD-L1 positive classification - Oncolytics